Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer

2016 ◽  
pp. 59-75
Author(s):  
Mark S. Talamonti
Keyword(s):  
Pancreatic Cancer ◽  
Treatment Strategies ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer

scholarly journals Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma

2021 ◽  
Vol 13 ◽  
pp. 175883592110458
Author(s):  
Siddharth Iyengar ◽  
Christopher Nevala-Plagemann ◽  
Ignacio Garrido-Laguna
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Treatment ◽  
Treatment Strategies ◽  
Ductal Adenocarcinoma ◽  
Pancreatic Tumors ◽  
Resection Margins ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Number Of Patients

Pancreatic cancer is the third leading cause of cancer-related mortality in the US. Outcomes for patients with pancreatic cancer are poor as curative approaches are only available to the minority of patients who have localized tumors for which surgery may be an option. The past decade has established fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) as the new standard of care following resection for fit patients with resectable pancreatic tumors. However, most patients will relapse and a large number of patients treated with upfront resection are unable to receive or complete adjuvant chemotherapy. There is therefore considerable interest in neoadjuvant treatment strategies for patients with resectable and borderline resectable pancreatic cancer as a way to provide early systemic treatment of micrometastatic disease, facilitate lymph node downstaging, and increase the likelihood of negative resection margins (R0). This review will focus on key aspects of completed trials evaluating adjuvant therapy in resectable pancreatic cancer and will provide an overview of emerging evidence supporting the use of neoadjuvant treatment strategies for both resectable and borderline resectable pancreatic cancer.

scholarly journals Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 978
Author(s):  
Nicolae Bacalbasa ◽  
Irina Balescu ◽  
Mihai Dimitriu ◽  
Cristian Balalau ◽  
Florentina Furtunescu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Portal Vein ◽  
Radical Surgery ◽  
Portal Vein Resection ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Venous Resection ◽  
Graft Thrombosis ◽  
Borderline Resectable Pancreatic Cancer ◽  
Vein Resection

Background: pancreatic cancer is one of the most lethal malignancies and a leading cause of cancer-related death worldwide. The only chance to improve the long-term outcomes of patients with pancreatic cancer is surgery with radical intent. Methods: in the present paper, we aim to describe a case series of 9 patients submitted to radical surgery for borderline resectable pancreatic cancer. Results: in all cases, negative resection margins were achieved. The types of venous resection consisted of tangential portal vein resection in four cases, circumferential portal vein resection with direct reanastomosis in one case and circumferential resection with graft placement in another four cases; postoperatively, one patient developed a vascular surgery-related complication consisting of graft thrombosis and thus necessitated prolonged anticoagulant therapy. Conclusions: extended venous resections can be a safe and efficient way to maximize the benefits of radical surgery in locally advanced, borderline resectable pancreatic cancer.

scholarly journals Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer

2014 ◽  
Vol 113 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Jordan Kharofa ◽  
Susan Tsai ◽  
Tracy Kelly ◽  
Clint Wood ◽  
Ben George ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemoradiation ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer

Tu1871 Validation of MD Anderson Group B Borderline Resectable Pancreatic Cancer

2013 ◽  
Vol 144 (5) ◽  
pp. S-868
Author(s):  
Tak Geun Oh ◽  
Moon Jae Chung ◽  
Seungmin Bang ◽  
Seung Woo Park ◽  
Jae Bock Chung ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Md Anderson ◽  
Group B

scholarly journals Borderline Resectable Pancreatic Cancer

2015 ◽  
Vol 6 (1) ◽  
pp. 63-68
Author(s):  
Bhargava Mullapudi ◽  
Patrick J. Hawkes ◽  
Asish Patel ◽  
Chandrakanth Are ◽  
Subhasis Misra
Keyword(s):  
Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer
Sign in / Sign up

Export Citation Format

Share Document